
Pap Follow-Up A-Z

Krysta Hood, DNP, RN, CRNP Nurse Practitioner Senior Alabama Department of Public Health

Objectives


- Review of follow-up steps including ASCCP 2019 Guidelines for Cervical Screening and Management through Case Study Application and Protocol
- A step-by-step guide for follow-up on abnormal pap smears.



Case Study


32 yo G2P2 no prior colpo history, smoker, no HPV vaccine series

Pap History: 2021 NIL -HPV 2020 NIL +HPV 2019 NIL +HPV



Standing Order

- · Consult on-call MD
- Any clinical situation without next steps
- Recommendation to Use Clinical Judgement
- Uncertain Management



Standing Order: UPDATE

- ASCCP App/Website and ADPH Protocol have the same recommendation for f/u
- Refer for colposcopy without a consult
- · Consult if indicated

Standing Order: UPDATE

 Refer to UAB or outside clinic for colposcopy as indicated by ASCCP guidelines



Consults

- · Age and pertinent history
- Clinical situation utilized
- Previous testing
- Indication for colposcopy if performed

Consults

- Colpo Histology
- Treatment Histology
- Include pertinent information regarding SCJ visualization, pathology report, and plan of care.
- Recommendation including Immediate and 5-year Risk Assessment with plan of care.

Consult Example

Append Note

32 yo G2P2 ASCCP 2019 Guidelines Return visit during pre-colpo surveillance- Use Clinical Judgement Pap History: 2021 NIL -HPV 2020 NIL +HPV 2019 NIL +HPV

Consult

- Make clear your initial plan of care.
- Don't just ask for recommendations or omit your plan of care.
- Refer for colposcopy or cotest in 1 year?

Consult

- · Assign note
- EHR message
- Add to District or County List for ADPH Colpo Clinic

ASCCP Interim Guidance for Timing and Treatment Procedures for Patients with Abnormal Cervical Screening Tests

May 26, 2020 - In light of the current unprecedented COVID-19 pandemic, and in settings where all non-essential medical office visits and elective procedures have been suspended ASCCP recommends the following:

- Individuals with low-grade cervical cancer screening tests may have postponement of diagnostic evaluations up to 6-1 months.
- Individuals with high-grade corvical cancer screening tests should have documented attempts to contact and diagnostic evaluation scheduled within 3 months.
- Individuals with high-grade cervical disease without suspected invasive disease should have documented attempts to contact and procedures scheduled within 3 months.
- 4. Individuals with suspected invasive disease should have contact attempted within 2 weeks and evaluation within 2 of that

Colpo List

Triage

- · High Risk
- Post-Colpo or LEEP Follow-up
- · Abnormal within past 12 months
- · Abnormal within past 6 months
- Lost to F/U

Colpo List Totals

- · District High Risk
- Post Colpo/LEEP
- 12 month
- 9 month
- 6 month
- Total

Colpo List

By County

 25 yo s/p LEEP UAB 7/20 Colpo/ECC due 2/2021, LEEP with CIN 2 + margins, + staining. Colpo 10/2019 Bibb.

Colposcopy Work-ups

 25 yo G2P1 LMP 3/23/2021 FPA 12/2020, current on Depo, STI cultures nonreactive.


Pap History:


- s/p LEEP UAB 7/20 Colpo/ECC due 2/2021, LEEP with CIN 2 + margins, + staining.
- · Colpo 10/2019 Bibb CIN 2


Pap History Documentation Reverse-Chronological Order- Most Recent First Diseases Procedure/Test Hospitalization Pau history 07/00/202 NL, pos 03/2018 ASCUS pos Characters left: 1872

Pap History Documentation Avoid Chronological Order


Hospitalization: 2007 LEEP 2010 NIL 2012 NIL 11/3/14 LGSIL and +HPV 2/13/15 LGSIL on Colpo 2/18/16 ASCUS with +HPV on Pap 5/13/16 LGSIL (CIN 1) colpo 5/25/17 Neg with +HPV on Pap 7/28/17 LGSIL (CIN 1) on Colpo 7/26/2018 NIL HPV POS 11/29/2018 LSIL CIN 1 colpo 12/23/2019 NIL HPV POS 02/20/2019 NIL PV POS 02/20/2020 Colpo/ ECC -Benign .











Pap History Documentation Avoid Use Procedure/Test Medical History Ansiety An
















References

Egemen D, Cheung LC, Chen X, et al. Risk estimates supporting the 2019 ASCCP Risk-Based Management Consensus Guidelines. J Low Genit Tract Dis 2020;24:132–43.

Perkins RB, Guido RS, Castle PE, et al. 2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis 2020;24:102–31.